Role of the E45K-reduced folate carrier gene mutation in methotrexate resistance in human leukemia cells
โ Scribed by Gifford, A J; Haber, M; Witt, T L; Whetstine, J R; Taub, J W; Matherly, L H; Norris, M D
- Book ID
- 110055212
- Publisher
- Nature Publishing Group
- Year
- 2002
- Tongue
- English
- Weight
- 464 KB
- Volume
- 16
- Category
- Article
- ISSN
- 0887-6924
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
## Abstract ## BACKGROUND Although the majority of children with acute lymphoblastic leukemia (ALL) are cured with combination chemotherapy containing methotrexate (MTX), drug resistance contributes to treatment failure for a substantial fraction of patients. The primary transporter for folates an
We have previously described a series of methotrexate (MTX)-selected CCRF-CEM sublines (CEM/MTX R1-3) displaying increased resistance to drugs associated with the multidrug resistance phenotype and have provided evidence that MDR1 P-glycoprotein contributes to multifactorial MTX resistance in these
Folate receptor-โฃ (FR-โฃ) is generally over-expressed in non-mucinous human ovarian carcinomas. The meaning of FR-โฃ over-expression and its role in the 5-methyltetrahydrofolic acid (N 5 -CH 3 -H 4 PteGlu) transport in such tumors is not clear, especially compared with the reduced folate carrier (RFC)